Citizens Jmp Cuts Evolent Health (NYSE:EVH) Price Target to $11.00

Evolent Health (NYSE:EVH) had its target price reduced by Citizens Jmp from $13.00 to $11.00 in a research note issued to investors on Monday morning,Benzinga reports. They currently have a market outperform rating on the technology company’s stock.

Several other brokerages also recently issued reports on EVH. Zacks Research downgraded shares of Evolent Health from a “hold” rating to a “strong sell” rating in a research report on Friday, October 10th. Piper Sandler upped their target price on shares of Evolent Health from $16.00 to $18.00 and gave the stock an “overweight” rating in a research note on Thursday, August 28th. BTIG Research dropped their price target on Evolent Health from $20.00 to $16.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. Truist Financial boosted their price target on Evolent Health from $14.00 to $16.00 and gave the company a “buy” rating in a report on Thursday, July 17th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $16.00 price target on shares of Evolent Health in a research report on Tuesday, September 9th. Twelve equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Evolent Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.00.

Evolent Health Stock Down 12.0%

Shares of Evolent Health stock opened at $4.43 on Monday. The company has a market capitalization of $520.92 million, a P/E ratio of -2.75 and a beta of 0.58. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.01 and a quick ratio of 1.01. The business has a 50-day moving average of $7.88 and a two-hundred day moving average of $8.96. Evolent Health has a 1 year low of $4.41 and a 1 year high of $14.53.

Evolent Health (NYSE:EVH) last issued its quarterly earnings data on Tuesday, June 4th. The technology company reported $0.21 earnings per share (EPS) for the quarter. Evolent Health had a positive return on equity of 1.83% and a negative net margin of 5.94%.The business had revenue of $427.70 million during the quarter. As a group, equities analysts predict that Evolent Health will post 0.08 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in EVH. Nisa Investment Advisors LLC raised its stake in shares of Evolent Health by 88.0% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,551 shares of the technology company’s stock worth $29,000 after purchasing an additional 1,194 shares in the last quarter. Parallel Advisors LLC raised its position in Evolent Health by 82.6% during the second quarter. Parallel Advisors LLC now owns 3,487 shares of the technology company’s stock worth $39,000 after acquiring an additional 1,577 shares in the last quarter. Police & Firemen s Retirement System of New Jersey lifted its stake in Evolent Health by 10.8% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 27,242 shares of the technology company’s stock valued at $307,000 after acquiring an additional 2,666 shares during the last quarter. Banque Cantonale Vaudoise acquired a new stake in Evolent Health in the first quarter valued at $25,000. Finally, Cetera Trust Company N.A grew its position in shares of Evolent Health by 47.3% in the 2nd quarter. Cetera Trust Company N.A now owns 9,725 shares of the technology company’s stock valued at $110,000 after acquiring an additional 3,125 shares during the period.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.